Navigation Links
So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market
Date:11/15/2007

Hoffmann-La Roche Inc. CEO George Abercrombie, Pfizer R&D Head Martin Mackay, HHS Deputy Secretary Tevi Troy, Former CMS Administrator & FDA Commissioner Mark McClellan Headline Agenda at FDA/CMS Summit 2007

WASHINGTON, Nov. 15 /PRNewswire-USNewswire/ -- It's shaping up to be a record year for drug approvals. Unfortunately for the biopharma sector and investors, it's a record low. The Food and Drug Administration is on track to grant marketing approval to 18 or fewer new drugs in 2007, and pipelines are not looking better in the coming years. For the research and development and marketing executives responsible for getting new drugs to customers, the level of unpredictability may be unprecedented. And Washington lawmakers and regulators are driving the uncertainty. Yesterday's blockbuster will not be the prototype for future drug development. Sweeping new legislation is reforming the FDA and changing how drugs are developed; Medicare is radically altering product economics; and Wall Street is looking for the next big thing.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071115/DC07546LOGO )

The FDA/CMS Summit, taking place December 6-7 in Washington, D.C., will feature the key decision makers from government and industry to help biopharmaceutical executives understand what regulatory and policy developments mean for research and commercial success.

"Today may look a lot like yesterday, but the rules of the game have fundamentally changed," said Cole Werble, editor-in-chief of The RPM Report, the lead sponsor of the conference. "Industry needs to learn what recent changes to FDA law mean and what the impact might hold for drug development and marketing. The FDA/CMS Summit provides leaders in industry key insight from policy-makers who have been involved in these changes."

The FDA/CMS Summit provides health care executives with an exclusive opportunity to have face-to-face dialogues with top policymakers and executives. The Summit is aimed at industry executives in all areas of responsibility who want to create successful strategies for dealing with FDA and CMS. Attendees will get practical, real-life lessons from some of the most experienced pharmaceutical and biotechnology executives on how they handle regulatory obstacles, and will also be able to benchmark their regulatory strategy against all other pharmaceutical and biotechnology companies.

Among the panels and participants scheduled for the Summit are:

- Did FDA Kill the Blockbuster? The Impact of FDA Changes on Research

and Development

-- Pfizer President, Global R&D Martin Mackay

-- Bristol-Myers Squibb SVP R&D Brian Daniels

-- Novartis SVP Global Clinical Development & Medical Affairs Glenn

Gormley

- Personalized Medicine: How Industry and Government can Make it Happen

-- Hoffmann La-Roche Inc. CEO George Abercrombie

- FDAAA and the New Active Surveillance System: What Does Data Mining

Mean for the Pharmaceutical Industry?

-- Engelberg Center for Health Care Reform Director, Former CMS

Administrator & FDA Commissioner Mark McClellan

-- FDA Assistant Commissioner for Policy Jeffrey Shuren

-- i3 Drug Safety SVP Alec Walker

- Paying for Innovation: CMS' Approach to Coverage

-- CMS Coverage & Analysis Group Director Steve Phurrough

- How the Government and Payors will Impact the Rx Market

-- CMS Center for Beneficiary Choices Chief Medical Officer Jeffrey

Kelman;

-- Former CMS Senior Advisor Larry Kocot;

-- Former Wellpoint Chief Pharmacy Officer and Founder of Doc Rock

Presents Robert Seidman

- Pharma in the Crosshairs: What are the Boundaries for Acceptable

Marketing?

-- First Assistant US Attorney, Boston Michael Loucks

-- Sidley Austin Partner and Former FDA Chief Counsel Daniel Troy

-- King & Spalding Partner John Bentivoglio

Complete agenda and registration information are available at http://www.windhover.com/fda-cms.

The RPM Report is a unique Windhover publication that examines FDA and CMS from a business perspective, designed to deliver not only the news from FDA and CMS but to tell executives what it all means to their companies. Register for a free online trial or a complimentary issue at http://www.rpmreport.com.

Sponsors for the FDA/CMS Summit are Foley Hoag LLP, Ogilvy Public Relations Worldwide, Avalere Health, the Personalized Medicine Coalition and PR Newswire.

Media sponsors are pharmalicensing.com, and bioscreening.com.

About Windhover Information

Windhover Information Inc. has led the field in providing analysis of the healthcare industry to decision-makers at all levels since the founding of its flagship publication, IN VIVO, The Business & Medicine Report, in 1983. Windhover provides its information and analysis in many formats, including print, electronic databases, international conferences and audio conferences. For more on the company's products and services, please see http://www.windhover.com.


'/>"/>
SOURCE Windhover Information Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011
3. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
4. Stem Cell Science Holds Opportunities as Important Tool for Diabetes Research Beyond Cell-Based Treatments
5. Nobel Award in Medicine Holds Strong Messsage for Animal Activists
6. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
7. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
8. Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions
9. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
10. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
11. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)...  Discovery Laboratories, Inc. (NASDAQ: DSCO ), ... surfactant therapies for respiratory diseases, today announced that ... award as a component of employment compensation for ... and Chief Executive Officer.  The award was approved ... 2016 and granted as an inducement material to ...
(Date:2/3/2016)... , Feb. 3, 2016 Ascendis Pharma A/S ... that applies its innovative TransCon technology to address significant ... an upcoming investor conference.Event:2016 Leerink Partners Global Healthcare Conference ... , Wednesday, February 10, 2016 Time:  , 11:55am ... . --> An audio webcast of this ...
(Date:2/3/2016)... N.J. , Feb. 3, 2016 ... totaling more than $1 million for researchers in ... working on health-related research that demonstrates exciting potential. ... round of funding for the New Jersey Health Foundation ... faculty members at these educational institutions— Princeton University, ...
(Date:2/3/2016)... ... 03, 2016 , ... ProMIS Neurosciences is currently in the ... misfolded, propagating strains of Amyloid beta involved in Alzheimer’s disease. The Company plans ... Following on from the first misfolded Amyloid beta target announced on Nov. 12, ...
Breaking Biology Technology:
(Date:2/2/2016)... 2016 This BCC Research report provides ... reviewing the recent advances in high throughput ‘omic ... field forward. Includes forecast through 2019. ... and opportunities that exist in the bioinformatic market. ... as well as IT and bioinformatics service providers. ...
(Date:2/2/2016)... 2016   Parabon NanoLabs (Parabon) announced ... Research Office and the Defense Forensics and Biometrics ... the company,s Snapshot Kinship Inference software ... generally, defense-related DNA forensics.  Although Snapshot is best ... and ancestry from DNA evidence), it also has ...
(Date:2/1/2016)... 2016  Today, the first day of American Heart ... develop a first of its kind workplace health solution ... In the first application of Watson ... ), and Welltok will create a new offering that ... analytics, delivered on Welltok,s health optimization platform. The effort ...
Breaking Biology News(10 mins):